Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study

Am Heart J. 2004 Dec;148(6):1047-52. doi: 10.1016/j.ahj.2004.05.046.

Authors

Olaf Schouten¹, Don Poldermans, Loes Visser, Miklos D Kertai, Jan Klein, Hero van Urk, Maarten L Simoons, Louis L van de Ven, Maarten Vermeulen, Jeroen J Bax, Thomas W Lameris, Eric Boersma

Affiliation

¹ Department of Surgery, Erasmus MC, Rotterdam, The Netherlands.

PMID: 15632892
DOI: 10.1016/j.ahj.2004.05.046

No abstract available

MeSH terms

Adrenergic beta-Antagonists / therapeutic use*
Adult
Bisoprolol / therapeutic use*
Cardiovascular Diseases / mortality*
Cardiovascular Diseases / prevention & control
Drug Therapy, Combination
Elective Surgical Procedures / mortality*
Fatty Acids, Monounsaturated / therapeutic use*
Fluvastatin
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Incidence
Indoles / therapeutic use*
Intraoperative Complications / mortality
Intraoperative Complications / prevention & control
Myocardial Infarction / epidemiology
Myocardial Infarction / prevention & control
Perioperative Care
Postoperative Complications / mortality
Postoperative Complications / prevention & control*
Premedication
Proportional Hazards Models
Randomized Controlled Trials as Topic
Research Design
Risk Assessment

Substances

Adrenergic beta-Antagonists
Fatty Acids, Monounsaturated
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Indoles
Fluvastatin
Bisoprolol